潜在的药物发现新靶点ADAMTS1  

ADAMTS1:a potential target for drug discovery

作　　者：彭健豪[1] 杜冠华[1] 

机构地区：[1]中国医学科学院北京协和医学院药物研究所国家药物筛选中心,北京100050

出　　处：《中国新药杂志》2009年第11期981-984,共4页Chinese Journal of New Drugs

摘　　要：含凝血酶敏感素1型基序的解聚素样金属蛋白酶(ADAMTS1)是新发现的蛋白水解酶,在哺乳动物组织中有较广泛的分布,其中,肺、心脏、脂肪组织和脑组织中表达较高。ADAMTS1在炎症情况下被诱导,具有抑制血管新生和内皮细胞增殖的作用。ADAMTS1主要通过水解蛋白聚糖和抑制血管新生的作用参与了肿瘤、动脉粥样硬化、脑缺血、表皮损伤修复等疾病的发生发展过程,激活或抑制该酶的活性,可以干预相关疾病的过程。因此,ADAMTS1有可能成为药物研发和疾病治疗的新靶点。A disintegrin and metalloprotease with thrombospondin type I motif （ADAMTS1） is a novel family of metalloproteinase which was found in various mammalian tissues and organs. ADAMTS1 is expressed at the highest levels in the lung, heart, adipose tissues, and brain. IL-1 has been shown to increase ADAMTS1 expression, which can inhibit angiogenesis and suppress endothelial cell proliferation. ADAMTS1 may contribute to the development of tumor, atherosclerosis, brain ischemia and repair of wounded tissue through degradation of proteoglycans and antiangiogenic properties. Activation or inhibition of the activity of ADAMTS1 will intervene the progress of these related diseases. Therefore, ADAMTS1 will be a potential target in the research and development of new drugs and treatment of diseases.

关 键 词：含凝血酶敏感素1型基序的解聚素样金属蛋白酶 金属蛋白酶 血管新生 

分 类 号：R977.3[医药卫生—药品]